Results of the study linking insulin resistance to the use of these antipsychotics are scheduled for presentation October 20th during the annual meeting of the American Academy of Child and Adolescent Psychiatry in Washington, D.C. (October 19-24)
For the study, the Johns Hopkins team evaluated 11 children, some overweight and others obese, who gained significant amounts of weight (a 10 percent weight increase) while taking the new-generation, or atypical, antipsychotic drugs olanzpine, quetiapine, and risperidone. Considerable weight gain is a common side effect of atypical antipsychotic medications, and is also one of the many factors that can contribute to insulin resistance.
All six children on moderate or high doses of one of these drugs, and three of five children on low doses, had evidence of insulin resistance, a condition in which the body cannot properly use the insulin it produces. This evidence included hypertension, high levels of triglycerides, low levels of high density lipoprotein cholesterol ("good" cholesterol) and increased levels of protein in the urine.
"The insulin resistance seen in these children was greater than what would be expected from weight gain alone, suggesting there is a factor distinct from excess weight that directly induces insulin resistance," says the study's lead author, Mark A. Riddle, M.D., director of the division of child and adolescent psychiatry at the Children's Center.
In general, this group of new-generation antipsychotics creates fewer side effects than older drugs used to treat debilitating psychiatric conditions such as schizophrenia, Riddle sa
'"/>
Contact: Jessica Collins
jcolli31@jhmi.edu
410-516-4570
Johns Hopkins Medical Institutions
20-Oct-2004